Perceptive Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Perceptive Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,333	Closed	-$567K	–	177
2015 Q3	$567K	Hold	3,333	–	–	0.05%	108
2015 Q2	$2.11M	Hold	3,333	–	–	0.13%	100
2015 Q1	$1.72M	Buy	3,333 +952	+40%	+$480K	0.13%	88
2014 Q4	$1.27M	Buy	+2,381	New	+$1.07M	0.11%	100
2013 Q3	–	Sell	-276	Closed	-$301K	–	120
2013 Q2	$301K	Buy	+276	New	+$308K	0.03%	71

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors's VIRX Position: Q4 2015 in Review

Perceptive Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2015, closing a stake of 3,333 shares — an estimated $567K sold.

Perceptive Advisors first reported a position in VIRX in Q2 2013 and held it in 5 quarters. The position peaked at $2.11M in Q2 2015. 55 funds tracked by Wall St. Rank hold VIRX as of Q4 2015.

Perceptive Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
Perceptive Advisors sold 3,333 Viracta Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $567K.
Perceptive Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
Perceptive Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $2.11M in Q2 2015.
55 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.